Photo of Bexis

JAMES M. BECK is Reed Smith's only Senior Life Sciences Policy Analyst, resident in the firm's Philadelphia office. He is the author of, among other things, Drug and Medical Device Product Liability Handbook (2004) (with Anthony Vale). He wrote the seminal law review article on off-label use cited by the Supreme Court in Buckman v. Plaintiffs Legal Committee. He has written more amicus briefs for the Product Liability Advisory Council than anyone else in the history of the organization, and in 2011 won PLAC's highest honor, the John P. Raleigh award. He has been a member of the American Law Institute (ALI) since 2005. He is the long-time editor of the newsletter of the ABA's Mass Torts Committee.  He is vice chair of the Class Actions and Multi-Plaintiff Litigation SLG of DRI's Drug and Device Committee.  He can be reached at jmbeck@reedsmith.com.  His LinkedIn page is here.

We’ve been keeping an eye on some interesting litigation in the District of Columbia, Iacangelo v. Georgetown University, C.A. No. 05-2086 (PLF). It’s not even a drug or device case, but rather a suit against a hospital and some doctors over their off-label use of certain “substances” in a medical procedure that went awry.

The Seventh Circuit just released its published opinion affirming the judgment entered on a defense verdict in an SSRI-suicide case. Giles v. Wyeth, No. 07-3149, slip op. (7th Cir. Feb. 12, 2009) (link here). Since Herrmann both tried the case and argued the appeal, we’ll be circumspect with what we say here.

Jeff

Here are three items we saw that might interest you:
First, on Monday, Judge Mark Bernstein (in Philadelphia Common Pleas) decertified a Neurontin off-label use class action, granted summary judgment on express warranty claims, and otherwise permitted the claims of two individual plaintiffs to proceed (they promptly asked for a continuance). Gregory Clark and Linda

Everyone keeps asking us when the Supreme Court will decide the big preemption case of Wyeth v. Levine. The parties argued the case on November 3; when will the Court rule?
We don’t have a clue.
The Supreme Court decides all cases argued during a Term before the Court adjourns for the Summer in the

It’s a pleasure to have an intelligent, articulate, defense-minded voice join us in the blogosphere.
(Lord knows, we can use all the help we can get.)
So we welcome aboard our new visitors who came through from Russell Jackson’s Consumer Class Actions and Mass Torts blog.
We’re also delighted to be spared the effort of